Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study.
about
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical managementDry eye: an inflammatory ocular diseaseOmalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature.Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitisA randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.Tacrolimus in the treatment of ocular diseases.Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface.Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.The use of topical tacrolimus 0.1% skin ointment for anterior segment conditions: a case series.Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis.Management of vernal keratoconjunctivitis.A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis.The efficacy of topical interferon alpha 2b treatment in refractory vernal keratoconjunctivitis.Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test.
P2860
Q26771818-040D4B41-7AE2-4129-9790-E732A4F9F7D7Q26852044-8D70E025-6357-41E3-87F2-D7E0BACF5383Q33740109-DA7302C8-9CCB-416F-A541-2E4469767436Q34882570-82819FA2-A773-4C56-8F32-2013A55706B3Q35171524-0F2362D9-F8B0-4170-9B0C-DD89ACEF4A53Q35187578-610CB891-B9DD-4439-8F98-194918C0DD41Q37858514-126F2201-F01E-4647-9852-95F29C88541BQ38040514-238B6D30-4E8F-4095-A04D-C214243F40D6Q38102592-293E365C-63C7-479D-A7D1-9A10996987F8Q38179488-CB792379-7A3A-4E9C-9D4C-B8CB7B371E13Q38184630-C18E3A03-CECB-4D75-BB25-83EAD8E597EEQ40940942-891EF625-AE2D-4F37-AE07-EE7DDFDDCC2BQ42227310-D0BB280C-86ED-494D-9F8B-4112848B1498Q42716988-0F2F4666-5589-452F-9D94-C88DC98D5739Q42745061-526475C1-B18D-45EA-BACE-1186FF73DFB9Q49395944-7592B2A9-D210-4065-B492-B578B7BE444FQ51353842-83244FF8-87A9-4333-B373-FD108A818734Q52665324-E94CAE1F-A824-4A5A-9DD9-774918DF0369
P2860
Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@en
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@nl
type
label
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@en
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@nl
prefLabel
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@en
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@nl
P2093
P2860
P1433
P1476
Topical tacrolimus 0.03% ointm ...... is: an open-label pilot study.
@en
P2093
David Zadok
Isaac Avni
Svetlana Rayvich
Vladimir Iskhakov
Yair Morad
Yariv Gerber
P2860
P304
P356
10.1080/02713680802149115
P577
2008-07-01T00:00:00Z